GYKI-52466
| Code | Size | Price |
|---|
| TAR-T21449-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T21449-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T21449-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
GYKI-52466 is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >50 μM for AMPA-, kainate- and NMDA-induced responses, respectively) used as a Skeletal muscle relaxant, orally active anticonvulsant, neuroprotective and anxiolytic in vivo.
CAS:
102771-26-6
Formula:
C17H15N3O2
Molecular Weight:
293.326
Purity:
0.98
SMILES:
CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1
References
1. Nayak PK, Kerr DS. Functional preservation of hippocampal CA1 by low-dose GYKI-52466 preconditioning in a rat model of hypoxic-ischemic brain injury. Brain Res. 2015 Jul 10;1613:100-9. doi: 10.1016/j.brainres.2015.04.004. Epub 2015 Apr 11. PubMed PMID: 25869178.
2. Wu A, Wang C, Niu L. Mechanism of inhibition of the GluA1 AMPA receptor channel opening by the 2,3-benzodiazepine compound GYKI 52466 and a N-methyl-carbamoyl derivative. Biochemistry. 2014 May 13;53(18):3033-41. doi: 10.1021/bi5002079. Epub 2014 May 1. PubMed PMID: 24738995; PubMed Central PMCID: PMC4025570.
3. Nayak PK, Kerr DS. Low-dose GYKI-52466: prophylactic preconditioning confers long-term neuroprotection and functional recovery following hypoxic-ischaemic brain injury. Neuroscience. 2013 Mar 1;232:128-38. doi: 10.1016/j.neuroscience.2012.11.063. Epub 2012 Dec 16. PubMed PMID: 23246617.
4. Srivastava R, Xi ZX, Gardner EL. Cocaine-taking and cocaine-seeking behaviors in rats remain stable after systemic administration of GYKI 52466: a non-competitive AMPA receptor antagonist. Neurosci Lett. 2012 Feb 6;508(2):106-9. doi: 10.1016/j.neulet.2011.12.028. Epub 2011 Dec 22. PubMed PMID: 22206835; PubMed Central PMCID: PMC3267379.